血管紧张素受体阻滞剂改善代谢综合征患者心脏外科结局
该研究采用倾向性匹配方法,从2998例冠状动脉旁路移植术患者中匹配出1351例,比较术前使用血管紧张素受体阻滞剂(ARB)、血管紧张素转换酶抑制剂(ACEI)或不使用肾素-血管紧张素系统抑制剂对代谢综合征患者术后30天并发症的影响。结果显示,术前使用ARB与较低的不良事件发生率相关,优于不使用肾素-血管紧张素系统抑制剂或使用ACEI。
要点
- 在代谢综合征患者中,术前使用ARB与术后30天不良事件风险降低相关。
- ARB的获益优于ACEI,提示两类药物在手术患者中可能存在疗效差异。
- 研究结果支持在此类患者中重新评估术前停用ARB的策略。
核心结论
- 在代谢综合征患者中,术前使用ARB而非ACEI与心脏术后30天不良事件发生率降低相关。
研究设计与样本
- 研究采用倾向性匹配方法,从2998例冠状动脉旁路移植术患者中匹配出1351例,根据术前使用ARB、ACEI或不使用肾素- angiotensin系统抑制剂分组。
主要发现
- 匹配队列中524例(38.8%)发生至少一次不良事件,全部患者中1184例(39.6%)发生不良事件。
- 在匹配队列中调整欧洲心脏手术风险评估系统(EuroSCORE)和代谢综合征后,术前使用ARB与不使用肾素-血管紧张素系统抑制剂相比,不良事件发生率的比值比为0.43(95%CI 0.19-0.99)。
- 术前使用ARB与使用ACEI相比,不良事件发生率的比值比为0.38(95%CI 0.16-0.88)。
临床怎么用
- 对于合并代谢综合征的冠状动脉旁路移植术患者,术前使用ARB可能降低术后30天不良事件风险,优于ACEI或不使用此类药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Perioperative use of angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEis) in patients undergoing cardiac operations remains controversial. The current practice of discontinuing renin-angiotensin-system inhibitors preoperatively may negate their beneficial effects in vulnerable populations, including patients with metabolic syndrome, who exhibit elevated renin-angiotensin system activity. We hypothesized that preoperative ARB use is associated with reduced incidence of postoperative complications, compared with ACEi or no drug, in patients with metabolic syndrome undergoing coronary artery bypass grafting. METHODS: We used propensity matching to derive a cohort of 1,351 patients from 2,998 who underwent coronary artery bypass grafting based on preoperative use of ARBs, ACEis, or no renin-angiotensin-system inhibitors. Our primary end point was a composite of adverse events occurring within 30 days after the operation: new-onset atrial fibrillation/flutter, arrhythmia requiring cardioversion, perioperative myocardial infarction, acute renal failure, need for dialysis, cerebrovascular accidents, acute respiratory failure, or perioperative death. RESULTS: At least one adverse event occurred in 524 (38.8%) of matched cohort patients (1,184 [39.6% of all patients]). Adjusting for European System for Cardiac Operative Risk Evaluation and metabolic syndrome in the matched cohort, preoperative use of ARBs was associated with a lower incidence of adverse events in patients with metabolic syndrome compared with preoperative use of no renin-angiotensin-system inhibitors (odds ratio, 0.43; 95% confidence interval, 0.19 to 0.99) or ACEis (odds ratio, 0.38; 95% confidence interval, 0.16 to 0.88). CONCLUSIONS: Preoperative use of ARBs, but not ACEis, confers a benefit within 30 days after cardiac operations in patients with metabolic syndrome, suggesting potential efficacy differences of these drug classes in reducing cardiovascular morbidity and death in ambulatory vs surgical patients.
引用
- Manning MW, Cooter M, Mathew J, et al. Angiotensin Receptor Blockade Improves Cardiac Surgical Outcomes in Patients With Metabolic Syndrome. Ann Thorac Surg. 2017. PMID: 28131423. doi:10.1016/j.athoracsur.2016.10.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。